Cure My Disease

Don't miss your cure!

 Log in / Sign up

Microembolization may outlast steroid shots for frozen shoulder

NCT ID NCT07696923

Disease control Sponsor: Shin Kong Wu Ho-Su Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Aug 06, 2026 · Updated 4 times

Summary

This study compares two treatments for frozen shoulder: a newer procedure called transcatheter arterial microembolization (TAME) and standard corticosteroid injections. TAME aims to reduce pain by blocking abnormal blood vessels in the shoulder, while steroids work by calming inflammation. The trial enrolls 94 adults with frozen shoulder and tracks pain, mobility, and quality of life over six months to see which approach offers better and longer-lasting relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcatheter arterial microembolization (TAME) and corticosteroid injection
What this could lead to
If TAME proves superior, it could offer a longer-lasting, non-surgical option for frozen shoulder relief.
What could go wrong
This is a single-center trial with 94 participants, so results may not apply broadly. TAME carries risks like temporary pain or artery spasm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 94 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1). age between 18 to 80 years old; * 2). shoulder pain for ≥ 1 month; * 3). \> 30% loss of passive range of motion (ROM) of the affected shoulder in external rotation and/or abduction, comparing with the sound side; * 4). pain VAS on maximal passive external rotation or abduction \> 4; * 5). showing willing to receive TAME, or shoulder joint injection, and attend regular physical therapy programs for 4 weeks. * 6). an empty or soft end feel during passive external rotation or abduction and/or night or rest pain. Exclusion Criteria: * 1). severe systemic disorders including cancer, stroke, or cardiopulmonary diseases; * 2). uncontrolled DM; * 3). rotator cuff tear or calcification of the affected shoulder; * 4). fracture, dislocation, or arthritis of the shoulder due to rheumatic disorders; - 5). a history of allergy to local anesthetics, corticosteroids, imipenem/cilastatin sodium or contrast medium; * 6). pregnancy; * 7). corticosteroid joint or subdeltoid bursa injection of the affected shoulder during the preceding three months; * 8). receiving TAME of the affected shoulder during the preceding six months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adhesive capsulitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bursitis Chronic Pain chronic pain syndrome frozen shoulder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adhesive capsulitis Chronic pain Corticosteroid injection Frozen shoulder Transcatheter arterial microembolization

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shin Kong Wu Ho-Su Memorial Hospital, Taipei,

    RECRUITING

    Taipei, 111, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.